Resverlogix Corp.

Resverlogix Corp.

March 05, 2007 09:15 ET

Resverlogix Announces Alzheimer's Research Program

ApoA-I emerging as new paradigm target for cognitive function

CALGARY, ALBERTA--(CCNMatthews - March 5, 2007) - Resverlogix Corp. (TSX:RVX) ("Resverlogix") is pleased to announce that it has initiated a research program dedicated to ApoA-I production and its therapeutic potential for disorders that effect cognitive function such as Alzheimer's Disease (AD). Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases such as Alzheimer's. Resverlogix has molecules potent and selective in raising plasma ApoA-I/HDL by increasing ApoA-I production that may beneficially impact AD. The Alzheimer's program will be developed in RVX Therapeutics', a wholly owned subsidiary of Resverlogix Corp. and does not signal a change in any other processes or programs currently underway at Resverlogix.

"There remains a great unmet need in this therapeutic area," stated Dr. Jan Johansson, Senior Vice President of Clinical Affairs at Resverlogix. "The growing body of evidence illustrating the ApoA-I/HDL protective role in neurodegenerative diseases such as Alzheimer's, make a compelling argument for our lead ApoA-I technology, NexVas PR. We are truly excited about this opportunity for this very important therapeutic area," Dr. Johansson further stated.

Neurodegenerative diseases such as Alzheimer's are one of the most debilitating in the developed world with a prevalence of an estimated 15 million people in the United States (U.S.) alone by 2050. In a report commissioned by the Alzheimer's Association, caregiver costs in the U.S. are estimated at US$36.5 billion which includes loss of productivity, absenteeism and worker replacement. The indirect costs of AD would also be greatly reduced; it is estimated that one-half to two-thirds of the cost of AD care stems from unpaid caregivers (often family members), who spend 16-35 hours per week looking after a person with AD. These figures underscore the importance of developing new therapies to aide the socioeconomic burden of AD.

"A core part of our business strategy is to build a robust pipeline of therapeutic opportunities for our potent ApoA-I raising molecules," stated Kenneth Lebioda, Senior Vice President of Business and Market Development. "Alzheimer's Disease represents the next important step for our lead technology NexVas PR into researching and developing novel therapeutics for the grievous burden that this disease has on health systems, families and patients," Mr. Lebioda added.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the main underlying cause of vascular diseases such as cardiovascular disease (CVD) and Alzheimer's Disease (AD). The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis, with a TGF- Beta inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information